

**Reviewer #1:**

The manuscript "Emerging Therapeutic Options for Non-Alcoholic Fatty Liver Disease: Cyclophilin Inhibitors, FGF21 Agonists, Dual and Pan PPAR Agonists - A Systematic Review" completely reviewed the clinical trial of using Cyclophilin Inhibitors, FGF21 Agonists, Dual and Pan PPAR Agonists in treatment of non-alcoholic fatty liver diseases. I think the manuscript is well-written and meaningful.

Thank you.

**Reviewer #2:**

-ABSTRACT • Please structure your Results and Conclusions scientifically. Be specific about your findings and their clinical implications.

\*Response: Both the results and conclusion sections in the abstract were structured with statistical data. The clinical implication was added to the conclusion.

-INTRODUCTION • Please include recent studies relevant to your topic. • In the last paragraph of the introduction, state the clinical implications of your study. What unanswered questions or problems remain? What questions does your study attempt to answer?

\*Response: We included a systematic review that analyzed PPAR agonists, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors, which evidenced clinically significant improvement in individual histological features of NASH. No systematic reviews were found on cyclophilin inhibitors, PPAR agonists, or FGF21 agonists for treating NAFLD. Information was added to the last paragraph of the introduction to emphasize the importance of clinicians being aware of the emerging therapies for NAFLD as well as the importance of further research to better characterize the efficacy, dosage, and length of treatment.

-METHODS • Consider adding Cochrane Library and Scopus to your list of databases.

\*Response: The list of databases was updated.

-RESULTS • Your Results should not solely consist of Tables. Please include the main findings in the main text.

\*Response: The main findings of each therapeutic class were described in the main text of the results section.

-In Figure 1, please correct the number of records identified from the databases, as it is not 3!

\*Response: The correct number of 803 was written in Figure 1.

**Reviewer #3:**

-The authors should specify the diagnostic criteria for NAFLD. Did all patients have liver biopsies?

\*Response: The criteria for inclusion/diagnosis varied per study. The Key Inclusion Criteria column in the tables now specifies which criteria the patient had to meet for each study, for example, NAFLD based on biopsy or elastography data, etc. Not all patients underwent a biopsy.